SlideShare a Scribd company logo
Cancer and the
Immune System
Amar Bhatt
Shirley Masand
Jaime Warmkessel
Immunology
Chapter 22
April 22, 2003
A Look Ahead
• Tumors and Metastasis
• Oncogenes and Cancer Induction
• Tumor Antigens
• Tumors and the Immune Response
• Immunotherapy
FATAL SYSTEM ERROR
An exception error has occurred at AP222003C22. A virus has been
detected. Quarantine has failed but the virus has been identified. Press the
Any key to return to windows in safe sesame mode.
Cancer and the
Immune System
Cancer
“altered self-cells that have escaped normal
growth regulation mechanisms”
neoplasm: tumor
benign vs. malignant
metastasis: spreading of cancerous cells via
blood or lymph to various tissues
Metastasis
22.1
Types of Cancers
carcinoma: endodermal/ectodermal tissue
leukemia/lymphoma: hematopoeitic stem cells
sarcoma: mesodermal connective tissues
What makes cancer “cancer”?
1. decreased requirements for growth
factors and serum
2. are no longer anchorage dependent
3. grow independently of density
normal cells:
eventually enter Go
confluent monolayer CHECKPOINT FAILURE
contact inhibition
Malignant Transformation
 are like in vitro cancers
 two phases
1.initiation (changes in genome)
2.promotion (proliferation)
Malignant Transformation
 chemical and physical carcinogens
 virally induced transformation
 cultured tumors: good models for study
 cancer cells are basically immortal
Oncogenes…
oncogene: “cancer
gene”; often found in
viral genomes
proto-oncogene:
cellular counterpart
which can be turned
into an oncogene
What can go right?
 induction of cellular
proliferation
 inhibition of cellular
proliferation, a.k.a. tumor-
suppressor genes
 regulation of programmed
cell death
What can go wrong?
 chromosomal translocations
 tandem repeats: HSRs
 mutations in proto-oncogenes
 viral integration
 growth factors and their receptors
Induction of Cancer
Fig. 22.2
Induction of Cancer
Lets Visualize!
 http://science.education.nih.gov/supplem
ents/nih1/cancer/activities/activity2_anim
ations.htm
Tumors of the Immune System
 Lymphomas
 Solid tumors w/in lymphoid tissue (bone marrow,
lymph nodes, thymus)
 Hodgkin’s & non-Hodgkin’s
 http://www.lymphomainfo.net/
 Leukemias
 Proliferate as single cells
 Acute or Chronic depending on the progression of
disease
 Acute- appear suddenly and progress rapidly;
arise is less mature cells (ie ALL, AML)
 Chronic- much less aggressive and develop
slowly; mature cells (ie CLL and CML)
Tumor Antigens
 TSTAs
 Tumor Specific Transplantation Antigen
 TATAs
 Tumor Associated Transplantation Antigen
TSTAs
 Unique to tumor cells
 DO NOT occur on normal cells in the body
 Novel proteins created my mutation presented
on class I MHC
 Can either be chemically/physically induced or
virally induced tumor antigens
Chemically/Physically Induced
Fig 22.7
•Specific Immunologic Response that can
Protect against later challenge by live cells
Of the same line but not other tumor-line
Cells.
•Methylcholanthrene / UV light
Virally Induced
 Express tumor antigens shared by all tumors induced
by the same virus
 Burkitt’s Lymphoma
 Epstein Barr
 HPV
Fig 22.9
TATAs
 NOT unique to tumor cells
 DO occur on normal cells in the body
 So where’s the problem?
 Fetal/adult presence
 Concentration of Growth Factors and
Growth Factor Receptors
TATAs cont’d
 Oncofetal Tumor Antigens (AFP & CEA)
 Normally appear in fetus before
immunocompetence
 Later recognized as non-self
 Oncogene Proteins
 Human Melanomas
Virally Induced Tumors
 Virally induced tumors have the same
antigens for each tumor caused by that
virus.
 HPV
Immune Response to Tumors
 Mostly a cell-mediated
response
 NK Cells
 Not MHC restricted
 Fc receptor binds to antibody
coated tumor cell  ADCC
 Chedieak-Higashi syndrome
 Macrophages
 Not MHC restricted
 Elicits ADCC
 TNF-alpha
 Immune Surveillance Theory
So, you have a tumor cell.
Now what?
 You need three things:
1. “See” the cancer
 Ternary complex and costimulation by B7
2. Activate lymphocytes
 Release IL-2, IFN-gamma, and TNF-alpha
3. Cancer cells must be susceptible to killing
 CTL lysis, macrophages, NK cells
Info From:
http://www.brown.edu/Courses/Bio_160/Projects1999/cancer/imevstca.html#Introduction
But if the body has all
these defenses, why do
so many people still have
cancer?
Conniving Cancer.
 Bad antibodies?
 Some antibodies do not protect against tumor
growth, but also ENHANCE it.
 Release of immunosuppressive cytokines
 transforming growth factor-beta (TGF-beta), interleukin-10
(IL-10) and vascular endothelial growth factor (VEGF)
 Hide and go Seeking Antigen
 Antigens actually seem to “hide” in the presence of
antibody
 Also, some cancer cells completely shed
themselves of the antigen
Effect TGF-beta IL-10 VEGF
Inhibition of T-cell growth
+ - +
Inhibition of CTL differentiation
+ + +
Inhibition of cytokine production
+ + -
Induction of T-cell anergy
+ - -
Downregulation of cytotoxic potential
+ + -
Inhibition of antigen presentation
+ + -
Shift in the Th1-Th2 balance towards
Th2
+ + -
Downregulation of
adhesion/costimulatory molecules
+ + -
Resistance to CTL-mediated lysis
- + -
Source: Chouaib et al 1997
Conniving Cancer cont.
 Reduction in
Class I MHC
Molecules
And the final blow…
 Lack of Co-
Stimulatory
Signal
Cancer Immunotherapy
 Manipulation of Co-Stimulatory
Signal
 Enhancement of APC Activity
 Cytokine Therapy
 Monoclonal Antibodies
 Cancer Vaccines
Manipulation of Co-Stimulatory Signal
 Tumor immunity can be enhanced by providing the
co-stimulatory signal necessary for activation of CTL
precursors (CTL-Ps)
 Fig. 22.11a
Manipulation of Co-Stimulatory Signal Cont.
 Basis for Vaccine
 Prevent metastasis after surgical removal or
primary melanoma in human patients
Enhancement of APC Activity
 GM-CSF (Granulocyte-macrophage colony-
stimulating factor)
remember: CSFs are cytokines that induce the
formation of distinct hematopoietic cell lines
 Fig 22.11b
Cytokine Therapy
 Use of recombinant cytokines (singly or
in combination) to augment an immune
response against cancer
 Via isolation and cloning of various cytokine
genes such as:
 IFN-α, β, and γ
 Interleukin 1, 2, 4, 5, and 12
 GM-CSF and Tumor necrosis factor (TNF)
Cytokine Therapy Cont.
I. Interferons
• Most clinical trials involve IFN-α
• Has been shown to induce tumor regression in
hematologic malignancies i.e. leukemias,
lymphomas, melanomas and breast cancer
• All types of IFN increase MHC I expression
• IFN-γ also has also been shown to increase
MHC
II expressionon macrophages and increase
activity of Tc cells, macrophages, and NKs
Cytokine Therapy Cont.
II. Tumor Necrosis Factors
• Kills some tumor cells
• Reduces proliferation of tumor cells without
affecting normal cells
How?
• Hemorrhagic necrosis and regression, inhibits
tumor induced vascularization (angio-genesis)
by damaging vascular endothelium
Cytokine Therapy Cont.
III. In Vitro-Activited LAK & TIL cells
A. Lymphocytes are activated against
tumor
antigens in vitro
• Cultured with x-irradiated tumor cells
in
presence of IL-2
• Generated lymphokine activated
killer
cells (LAKs), which kill tumor cells
without affecting normal cells
In Vitro-Activated LAK and TIF cells Cont.
B. Tumors contain lymphocytes that have
infiltrated tumor and act in anti-tumor
response
• via biopsy, obtained cells and
expanded population in vitro with
• generated tumor-infiltrating lympho-
cytes (TILs)
Monoclonal Antibodies
• Anti-idiotype
• Growth Factors
-HER2
• Immunotoxins
Cancer Vaccines
• Genetic
 Biochemical
HPV
Human Papilloma Virus
 E6
 E7
From Normal to Abnormal:
For more info
 HPV
 Cancer Vaccines
This Day Has
Been Brought to
you By the
Letter…
C
C is for Cancer!

More Related Content

Similar to CANCER3C (1).PPT

11. tumour immunology.pptx
11. tumour immunology.pptx11. tumour immunology.pptx
11. tumour immunology.pptx
nedalalazzwy
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
Pashon Hana
 
Cancer immunology.pptx
Cancer immunology.pptxCancer immunology.pptx
Cancer immunology.pptx
Annie Annie
 
Tumourclasss
TumourclasssTumourclasss
Tumourclasss
Bruno Mmassy
 
Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
madhursejwal
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
Annie Annie
 
Cancer and immune system
Cancer and immune systemCancer and immune system
Cancer and immune system
NidaSajjad2
 
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of TumorsTUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
Dr. Roopam Jain
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
College of Agriculture
 
IMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORSIMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORS
Saajida Sultaana
 
Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notes
Bruno Mmassy
 
Immunosurveillance,
Immunosurveillance,Immunosurveillance,
Immunosurveillance,
farranajwa
 
Immunobiology of cancer
Immunobiology of cancerImmunobiology of cancer
Immunobiology of cancer
Joana Ribeiro Paulo
 
Pharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantporPharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantpor
mmoney1
 
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
SIVASWAROOP YARASI
 
Monoclonal antibodies2
Monoclonal antibodies2Monoclonal antibodies2
Monoclonal antibodies2
Barbara Umolac
 
14.tumor immunology and immunotherapy
14.tumor  immunology and immunotherapy14.tumor  immunology and immunotherapy
14.tumor immunology and immunotherapy
Sweta Shrestha
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodies
Barbara Umolac
 
Cancer immunology
Cancer immunologyCancer immunology
Cancer immunology
naveenagirish
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx

Similar to CANCER3C (1).PPT (20)

11. tumour immunology.pptx
11. tumour immunology.pptx11. tumour immunology.pptx
11. tumour immunology.pptx
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
 
Cancer immunology.pptx
Cancer immunology.pptxCancer immunology.pptx
Cancer immunology.pptx
 
Tumourclasss
TumourclasssTumourclasss
Tumourclasss
 
Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
 
Cancer and immune system
Cancer and immune systemCancer and immune system
Cancer and immune system
 
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of TumorsTUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
 
IMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORSIMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORS
 
Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notes
 
Immunosurveillance,
Immunosurveillance,Immunosurveillance,
Immunosurveillance,
 
Immunobiology of cancer
Immunobiology of cancerImmunobiology of cancer
Immunobiology of cancer
 
Pharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantporPharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantpor
 
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
 
Monoclonal antibodies2
Monoclonal antibodies2Monoclonal antibodies2
Monoclonal antibodies2
 
14.tumor immunology and immunotherapy
14.tumor  immunology and immunotherapy14.tumor  immunology and immunotherapy
14.tumor immunology and immunotherapy
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodies
 
Cancer immunology
Cancer immunologyCancer immunology
Cancer immunology
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
 

More from UmaShanksr

li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...
li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...
li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...
UmaShanksr
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
UmaShanksr
 
cvs2-121214034908-phpapp02.pdf
cvs2-121214034908-phpapp02.pdfcvs2-121214034908-phpapp02.pdf
cvs2-121214034908-phpapp02.pdf
UmaShanksr
 
5cb6bf1ceca06.ppsx
5cb6bf1ceca06.ppsx5cb6bf1ceca06.ppsx
5cb6bf1ceca06.ppsx
UmaShanksr
 
CardiacPsychiatry-2019.pptx
CardiacPsychiatry-2019.pptxCardiacPsychiatry-2019.pptx
CardiacPsychiatry-2019.pptx
UmaShanksr
 
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
UmaShanksr
 
Management-of-CAD.ppt
Management-of-CAD.pptManagement-of-CAD.ppt
Management-of-CAD.ppt
UmaShanksr
 
PostoperativeTransfusionReactiondidactic_508.pptx
PostoperativeTransfusionReactiondidactic_508.pptxPostoperativeTransfusionReactiondidactic_508.pptx
PostoperativeTransfusionReactiondidactic_508.pptx
UmaShanksr
 
att1_menis_sep09.ppt
att1_menis_sep09.pptatt1_menis_sep09.ppt
att1_menis_sep09.ppt
UmaShanksr
 
Patho-2017.pptx
Patho-2017.pptxPatho-2017.pptx
Patho-2017.pptx
UmaShanksr
 
salivary_glands.pptx
salivary_glands.pptxsalivary_glands.pptx
salivary_glands.pptx
UmaShanksr
 
TUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.pptTUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.ppt
UmaShanksr
 
59440-262_Slides.pptx
59440-262_Slides.pptx59440-262_Slides.pptx
59440-262_Slides.pptx
UmaShanksr
 
Ppt Uma.pptx
Ppt Uma.pptxPpt Uma.pptx
Ppt Uma.pptx
UmaShanksr
 
Lecture101210.ppt
Lecture101210.pptLecture101210.ppt
Lecture101210.ppt
UmaShanksr
 
lec_16_hematology_immunity_2.pptx
lec_16_hematology_immunity_2.pptxlec_16_hematology_immunity_2.pptx
lec_16_hematology_immunity_2.pptx
UmaShanksr
 
3_2018_12_28!09_53_56_PM.ppt
3_2018_12_28!09_53_56_PM.ppt3_2018_12_28!09_53_56_PM.ppt
3_2018_12_28!09_53_56_PM.ppt
UmaShanksr
 

More from UmaShanksr (17)

li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...
li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...
li j et al_lancet_2015_st-segment elevation myocardial infarction in china fr...
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
 
cvs2-121214034908-phpapp02.pdf
cvs2-121214034908-phpapp02.pdfcvs2-121214034908-phpapp02.pdf
cvs2-121214034908-phpapp02.pdf
 
5cb6bf1ceca06.ppsx
5cb6bf1ceca06.ppsx5cb6bf1ceca06.ppsx
5cb6bf1ceca06.ppsx
 
CardiacPsychiatry-2019.pptx
CardiacPsychiatry-2019.pptxCardiacPsychiatry-2019.pptx
CardiacPsychiatry-2019.pptx
 
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
 
Management-of-CAD.ppt
Management-of-CAD.pptManagement-of-CAD.ppt
Management-of-CAD.ppt
 
PostoperativeTransfusionReactiondidactic_508.pptx
PostoperativeTransfusionReactiondidactic_508.pptxPostoperativeTransfusionReactiondidactic_508.pptx
PostoperativeTransfusionReactiondidactic_508.pptx
 
att1_menis_sep09.ppt
att1_menis_sep09.pptatt1_menis_sep09.ppt
att1_menis_sep09.ppt
 
Patho-2017.pptx
Patho-2017.pptxPatho-2017.pptx
Patho-2017.pptx
 
salivary_glands.pptx
salivary_glands.pptxsalivary_glands.pptx
salivary_glands.pptx
 
TUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.pptTUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.ppt
 
59440-262_Slides.pptx
59440-262_Slides.pptx59440-262_Slides.pptx
59440-262_Slides.pptx
 
Ppt Uma.pptx
Ppt Uma.pptxPpt Uma.pptx
Ppt Uma.pptx
 
Lecture101210.ppt
Lecture101210.pptLecture101210.ppt
Lecture101210.ppt
 
lec_16_hematology_immunity_2.pptx
lec_16_hematology_immunity_2.pptxlec_16_hematology_immunity_2.pptx
lec_16_hematology_immunity_2.pptx
 
3_2018_12_28!09_53_56_PM.ppt
3_2018_12_28!09_53_56_PM.ppt3_2018_12_28!09_53_56_PM.ppt
3_2018_12_28!09_53_56_PM.ppt
 

Recently uploaded

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 

Recently uploaded (20)

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 

CANCER3C (1).PPT

  • 1. Cancer and the Immune System Amar Bhatt Shirley Masand Jaime Warmkessel Immunology Chapter 22 April 22, 2003
  • 2. A Look Ahead • Tumors and Metastasis • Oncogenes and Cancer Induction • Tumor Antigens • Tumors and the Immune Response • Immunotherapy
  • 3. FATAL SYSTEM ERROR An exception error has occurred at AP222003C22. A virus has been detected. Quarantine has failed but the virus has been identified. Press the Any key to return to windows in safe sesame mode.
  • 5. Cancer “altered self-cells that have escaped normal growth regulation mechanisms” neoplasm: tumor benign vs. malignant metastasis: spreading of cancerous cells via blood or lymph to various tissues
  • 7. Types of Cancers carcinoma: endodermal/ectodermal tissue leukemia/lymphoma: hematopoeitic stem cells sarcoma: mesodermal connective tissues
  • 8. What makes cancer “cancer”? 1. decreased requirements for growth factors and serum 2. are no longer anchorage dependent 3. grow independently of density normal cells: eventually enter Go confluent monolayer CHECKPOINT FAILURE contact inhibition
  • 9. Malignant Transformation  are like in vitro cancers  two phases 1.initiation (changes in genome) 2.promotion (proliferation)
  • 10. Malignant Transformation  chemical and physical carcinogens  virally induced transformation  cultured tumors: good models for study  cancer cells are basically immortal
  • 11. Oncogenes… oncogene: “cancer gene”; often found in viral genomes proto-oncogene: cellular counterpart which can be turned into an oncogene
  • 12. What can go right?  induction of cellular proliferation  inhibition of cellular proliferation, a.k.a. tumor- suppressor genes  regulation of programmed cell death
  • 13. What can go wrong?  chromosomal translocations  tandem repeats: HSRs  mutations in proto-oncogenes  viral integration  growth factors and their receptors
  • 17. Tumors of the Immune System  Lymphomas  Solid tumors w/in lymphoid tissue (bone marrow, lymph nodes, thymus)  Hodgkin’s & non-Hodgkin’s  http://www.lymphomainfo.net/  Leukemias  Proliferate as single cells  Acute or Chronic depending on the progression of disease  Acute- appear suddenly and progress rapidly; arise is less mature cells (ie ALL, AML)  Chronic- much less aggressive and develop slowly; mature cells (ie CLL and CML)
  • 18. Tumor Antigens  TSTAs  Tumor Specific Transplantation Antigen  TATAs  Tumor Associated Transplantation Antigen
  • 19. TSTAs  Unique to tumor cells  DO NOT occur on normal cells in the body  Novel proteins created my mutation presented on class I MHC  Can either be chemically/physically induced or virally induced tumor antigens
  • 20. Chemically/Physically Induced Fig 22.7 •Specific Immunologic Response that can Protect against later challenge by live cells Of the same line but not other tumor-line Cells. •Methylcholanthrene / UV light
  • 21. Virally Induced  Express tumor antigens shared by all tumors induced by the same virus  Burkitt’s Lymphoma  Epstein Barr  HPV Fig 22.9
  • 22. TATAs  NOT unique to tumor cells  DO occur on normal cells in the body  So where’s the problem?  Fetal/adult presence  Concentration of Growth Factors and Growth Factor Receptors
  • 23. TATAs cont’d  Oncofetal Tumor Antigens (AFP & CEA)  Normally appear in fetus before immunocompetence  Later recognized as non-self  Oncogene Proteins  Human Melanomas
  • 24. Virally Induced Tumors  Virally induced tumors have the same antigens for each tumor caused by that virus.  HPV
  • 25. Immune Response to Tumors  Mostly a cell-mediated response  NK Cells  Not MHC restricted  Fc receptor binds to antibody coated tumor cell  ADCC  Chedieak-Higashi syndrome  Macrophages  Not MHC restricted  Elicits ADCC  TNF-alpha  Immune Surveillance Theory
  • 26. So, you have a tumor cell. Now what?  You need three things: 1. “See” the cancer  Ternary complex and costimulation by B7 2. Activate lymphocytes  Release IL-2, IFN-gamma, and TNF-alpha 3. Cancer cells must be susceptible to killing  CTL lysis, macrophages, NK cells Info From: http://www.brown.edu/Courses/Bio_160/Projects1999/cancer/imevstca.html#Introduction
  • 27. But if the body has all these defenses, why do so many people still have cancer?
  • 28. Conniving Cancer.  Bad antibodies?  Some antibodies do not protect against tumor growth, but also ENHANCE it.  Release of immunosuppressive cytokines  transforming growth factor-beta (TGF-beta), interleukin-10 (IL-10) and vascular endothelial growth factor (VEGF)  Hide and go Seeking Antigen  Antigens actually seem to “hide” in the presence of antibody  Also, some cancer cells completely shed themselves of the antigen
  • 29. Effect TGF-beta IL-10 VEGF Inhibition of T-cell growth + - + Inhibition of CTL differentiation + + + Inhibition of cytokine production + + - Induction of T-cell anergy + - - Downregulation of cytotoxic potential + + - Inhibition of antigen presentation + + - Shift in the Th1-Th2 balance towards Th2 + + - Downregulation of adhesion/costimulatory molecules + + - Resistance to CTL-mediated lysis - + - Source: Chouaib et al 1997
  • 30. Conniving Cancer cont.  Reduction in Class I MHC Molecules
  • 31. And the final blow…  Lack of Co- Stimulatory Signal
  • 32.
  • 33.
  • 34. Cancer Immunotherapy  Manipulation of Co-Stimulatory Signal  Enhancement of APC Activity  Cytokine Therapy  Monoclonal Antibodies  Cancer Vaccines
  • 35. Manipulation of Co-Stimulatory Signal  Tumor immunity can be enhanced by providing the co-stimulatory signal necessary for activation of CTL precursors (CTL-Ps)  Fig. 22.11a
  • 36. Manipulation of Co-Stimulatory Signal Cont.  Basis for Vaccine  Prevent metastasis after surgical removal or primary melanoma in human patients
  • 37. Enhancement of APC Activity  GM-CSF (Granulocyte-macrophage colony- stimulating factor) remember: CSFs are cytokines that induce the formation of distinct hematopoietic cell lines  Fig 22.11b
  • 38. Cytokine Therapy  Use of recombinant cytokines (singly or in combination) to augment an immune response against cancer  Via isolation and cloning of various cytokine genes such as:  IFN-α, β, and γ  Interleukin 1, 2, 4, 5, and 12  GM-CSF and Tumor necrosis factor (TNF)
  • 39. Cytokine Therapy Cont. I. Interferons • Most clinical trials involve IFN-α • Has been shown to induce tumor regression in hematologic malignancies i.e. leukemias, lymphomas, melanomas and breast cancer • All types of IFN increase MHC I expression • IFN-γ also has also been shown to increase MHC II expressionon macrophages and increase activity of Tc cells, macrophages, and NKs
  • 40. Cytokine Therapy Cont. II. Tumor Necrosis Factors • Kills some tumor cells • Reduces proliferation of tumor cells without affecting normal cells How? • Hemorrhagic necrosis and regression, inhibits tumor induced vascularization (angio-genesis) by damaging vascular endothelium
  • 41. Cytokine Therapy Cont. III. In Vitro-Activited LAK & TIL cells A. Lymphocytes are activated against tumor antigens in vitro • Cultured with x-irradiated tumor cells in presence of IL-2 • Generated lymphokine activated killer cells (LAKs), which kill tumor cells without affecting normal cells
  • 42. In Vitro-Activated LAK and TIF cells Cont. B. Tumors contain lymphocytes that have infiltrated tumor and act in anti-tumor response • via biopsy, obtained cells and expanded population in vitro with • generated tumor-infiltrating lympho- cytes (TILs)
  • 43. Monoclonal Antibodies • Anti-idiotype • Growth Factors -HER2 • Immunotoxins
  • 44.
  • 47. From Normal to Abnormal:
  • 48. For more info  HPV  Cancer Vaccines
  • 49. This Day Has Been Brought to you By the Letter… C C is for Cancer!